Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kimberly A Roehl

Showing results (1-10 of 123) with videos related to

Pageof 13
Sort By:
The Journal of Urology|July 12, 2005
Predictors of subsequent prostate cancer in men with a prostate specific antigen of 2.6 to 4.0 ng/ml and an initially negative biopsyScott E Eggener, Kimberly A Roehl, William J Catalona
The Journal of Urology|August 21, 2002
Robustness of free prostate specific antigen measurements to reduce unnecessary biopsies in the 2.6 to 4.0 ng./ml. rangeKimberly A Roehl, Jo Ann V Antenor, William J Catalona
The Journal of Urology|May 7, 2002
Serial biopsy results in prostate cancer screening studyKimberly A Roehl, Jo Ann V Antenor, William J Catalona
Urology|March 23, 2005
High-grade prostatic intraepithelial neoplasia in needle biopsy as risk factor for detection of adenocarcinoma: current level of risk in screening populationNeriman Gokden, Kimberly A Roehl, William J Catalona, et al.
Urology|March 11, 2008
Complications of open radical retropubic prostatectomy in potential candidates for active monitoringStacy Loeb, Kimberly A Roehl, Brian T Helfand, et al.
European Urology|April 11, 2008
Long-term rates of undetectable PSA with initial observation and delayed salvage radiotherapy after radical prostatectomyStacy Loeb, Kimberly A Roehl, Davis P Viprakasit, et al.
Urology|June 19, 2007
Intermediate-term potency, continence, and survival outcomes of radical prostatectomy for clinically high-risk or locally advanced prostate cancerStacy Loeb, Norm D Smith, Kimberly A Roehl, et al.
Urology|April 26, 2008
Combined prostate-specific antigen density and biopsy features to predict "clinically insignificant" prostate cancerStacy Loeb, Kimberly A Roehl, C Shad Thaxton, et al.
The Journal of Urology|September 6, 2006
Prediagnosis prostate specific antigen velocity is associated with risk of prostate cancer progression following brachytherapy and external beam radiation therapyScott E Eggener, Kimberly A Roehl, Ofer Yossepowitch, et al.
BJU International|March 7, 2008
Is the utility of prostate-specific antigen velocity for prostate cancer detection affected by age?Stacy Loeb, Kimberly A Roehl, William J Catalona, et al.
Pageof 13

Showing results (1-10 of 123) with videos related to

Sort By:
Pageof 13
The Journal of Urology|July 12, 2005
Predictors of subsequent prostate cancer in men with a prostate specific antigen of 2.6 to 4.0 ng/ml and an initially negative biopsyScott E Eggener, Kimberly A Roehl, William J Catalona
The Journal of Urology|August 21, 2002
Robustness of free prostate specific antigen measurements to reduce unnecessary biopsies in the 2.6 to 4.0 ng./ml. rangeKimberly A Roehl, Jo Ann V Antenor, William J Catalona
The Journal of Urology|May 7, 2002
Serial biopsy results in prostate cancer screening studyKimberly A Roehl, Jo Ann V Antenor, William J Catalona
Urology|March 23, 2005
High-grade prostatic intraepithelial neoplasia in needle biopsy as risk factor for detection of adenocarcinoma: current level of risk in screening populationNeriman Gokden, Kimberly A Roehl, William J Catalona, et al.
Urology|March 11, 2008
Complications of open radical retropubic prostatectomy in potential candidates for active monitoringStacy Loeb, Kimberly A Roehl, Brian T Helfand, et al.
European Urology|April 11, 2008
Long-term rates of undetectable PSA with initial observation and delayed salvage radiotherapy after radical prostatectomyStacy Loeb, Kimberly A Roehl, Davis P Viprakasit, et al.
Urology|June 19, 2007
Intermediate-term potency, continence, and survival outcomes of radical prostatectomy for clinically high-risk or locally advanced prostate cancerStacy Loeb, Norm D Smith, Kimberly A Roehl, et al.
Urology|April 26, 2008
Combined prostate-specific antigen density and biopsy features to predict "clinically insignificant" prostate cancerStacy Loeb, Kimberly A Roehl, C Shad Thaxton, et al.
The Journal of Urology|September 6, 2006
Prediagnosis prostate specific antigen velocity is associated with risk of prostate cancer progression following brachytherapy and external beam radiation therapyScott E Eggener, Kimberly A Roehl, Ofer Yossepowitch, et al.
BJU International|March 7, 2008
Is the utility of prostate-specific antigen velocity for prostate cancer detection affected by age?Stacy Loeb, Kimberly A Roehl, William J Catalona, et al.
Pageof 13